Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1CNS 1Breast 1

Conditions

Mesothelioma, Malignant 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 280Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × fresolimumab × Clear all
NCT01472731 2024-05-06

Safety and Imaging Study of GC1008 in Glioma

University Medical Center Groningen

Phase 2 Completed
12 enrolled
CNS

Brain Neoplasms

NCT01112293 2020-04-10

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
14 enrolled 10 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01401062 2019-03-05

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

Weill Medical College of Cornell University

Phase 2 Completed
23 enrolled 8 charts
Breast

Breast Neoplasms, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡